Rise and shine, everyone, another busy day is on the way. Most every day is busy, though, is it not? Well, no matter. Busy is good, as they say. So time to get cracking, which means we would like to invite you to join us for our ritual cup of stimulation, which is a much-needed boost this morning, thanks to a growing to-do list of meetings and phone calls and deadlines — oh my! Meanwhile, we have gathered a few items of interest to help you along. Hopefully, this will be equally stimulating. Hope you conquer the world and stay in touch …

Allergan (AGN) disclosed that its experimental depression drug, rapastinel, failed to improve symptoms more than placebo when added to existing antidepressants in not one but three studies, STAT writes. The drug was the cornerstone of a $560 million deal to buy Naurex four years ago and follows a string of recent setbacks for the big drug maker, which includes new competition to its best-selling Botox treatment. However, Wall Street analysts noted Allergan management recently sent mixed signals about the rapastinel trial results.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy